Compare GSK plc (GSK) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ABRDN Physical Gold Shares ETF — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while ABRDN Physical Gold Shares ETF trades at $38.03. The key difference: GSK plc pays a 3.49% dividend while ABRDN Physical Gold Shares ETF pays none, and GSK plc is trading nearer its 52-week high, ABRDN Physical Gold Shares ETF nearer its low. Which is the better fit depends on your goals.
| GSK | SGOL | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $61.18 | $51.41 |
52-Week Low | $36.20 | $31.18 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
SGOL is currently trading at $38.02, down 1.53% for the day amid broader gold market weakness. Technical indicators show a bearish trend with moving averages signaling strong selling pressure while oscillators remain neutral. The stock faces resistance at $39 with support established at $38. Recent market sentiment reflects concerns about Federal Reserve policy and dollar strength impacting gold prices.
The outlook remains cautious as gold faces headwinds from potential rate hikes and dollar stabilization. Investment opportunity exists if the stock holds the $38 support level, but risks include continued Fed hawkishness and economic data surprises. Gold's traditional safe-haven appeal provides some downside protection amid geopolitical tensions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
